Hester Biosciences Limited (BOM:524669)
2,187.65
+81.95 (3.89%)
At close: Oct 6, 2026
Hester Biosciences Revenue
Hester Biosciences had revenue of 772.44M INR in the quarter ending June 30, 2026, a decrease of -8.16%. This brings the company's revenue in the last twelve months to 3.27B, up 4.12% year-over-year. In the fiscal year ending March 31, 2026, Hester Biosciences had annual revenue of 3.34B with 6.93% growth. That makes Hester Biosciences the world's #30,573 largest public company by revenue and #2,105 in India.
Revenue (ttm)
3.27B
Revenue Growth
+4.12%
P/S Ratio
5.69
Revenue / Employee
6.78M
Employees
483
Market Cap
18.61B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 3.34B | 216.47M | 6.93% |
| Mar 31, 2025 | 3.12B | 12.80M | 0.41% |
| Mar 31, 2024 | 3.11B | 329.89M | 11.86% |
| Mar 31, 2023 | 2.78B | 315.58M | 12.79% |
| Mar 31, 2022 | 2.47B | 289.51M | 13.30% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Huhtamaki India | 26.12B |
| Paramount Communications | 19.92B |
| Thirumalai Chemicals | 18.32B |
| Media Matrix Worldwide | 14.52B |
| Oriental Aromatics | 10.65B |
| NGL Fine-Chem | 5.36B |
| RACL Geartech | 5.22B |
| EIH Associated Hotels | 3.81B |
Hester Biosciences News
- 8 months ago - Hester Biosciences Q3 PAT jumps 140% to Rs 10.67cr - The Times of India
- 1 year ago - Hester Biosciences shares rally 15% as Q1 profit soars 131% YoY to Rs 17.3 crore, revenue rises 2% - Business Upturn
- 1 year ago - India's Animal Healthcare Industry on a High-Growth Trajectory, Projected to Reach USD 2.0 Billion by 2034| Exclusive Report by Transparency Market Research Inc. - Benzinga
- 1 year ago - Hester Biosciences shares surge over 11% following strong Q2 FY25 performance - Business Upturn
- 1 year ago - Hester Biosciences Q2: Revenue jumps 18.8% YoY to ₹83.69 crores, PAT surges 107.4% YoY to ₹8.39 crores - Business Upturn